Identification of promiscuous HLA-DR-restricted CD4⁺ T-cell epitopes on the cancer-testis antigen HCA587 - PubMed (original) (raw)
. 2011 Aug;102(8):1455-61.
doi: 10.1111/j.1349-7006.2011.01986.x. Epub 2011 Jun 27.
Affiliations
- PMID: 21595801
- DOI: 10.1111/j.1349-7006.2011.01986.x
Free article
Identification of promiscuous HLA-DR-restricted CD4⁺ T-cell epitopes on the cancer-testis antigen HCA587
Weigang Wen et al. Cancer Sci. 2011 Aug.
Free article
Abstract
The cancer testis antigen HCA587 is an attractive candidate for T cell-based immunotherapy because it is overexpressed in a wide spectrum of malignant tumors but not normal tissues, except testis. Several CTL epitopes derived from HCA587 have been described. Our aim was to identify helper T lymphocyte epitopes of HCA587 for the optimization of T cell-based immunotherapies against HCA587-expressing tumors. Candidate helper T lymphocyte epitopes for HCA587 were predicted using the SYFPEITHI algorithm and were tested for their ability to induce helper T lymphocyte responses by in vitro peptide vaccination of CD4(+) T lymphocytes from healthy individuals and hepatocellular carcinoma patients. Four CD4(+) T-cell epitopes for HCA587 (p43-57, p145-159, p186-200 and p249-263) were identified. Among them, the p43-57 epitope was shown to be naturally processed and presented by HCA587-expressing tumor cells as well as autologous dendritic cells pulsed with whole-protein HCA587. Notably, this epitope behaved as a promiscuous T-cell epitope as it stimulated T cells in the context of more than one HLA class II allele. Thus, p43-57 is the first HCA587-derived major histocompatibility complex class II-restricted epitope to fulfil all prerequisites for use as a peptide vaccine in patients with HCA587-expressing tumors.
© 2011 Japanese Cancer Association.
Similar articles
- Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
Kobayashi H, Nagato T, Sato K, Aoki N, Kimura S, Murakami M, Iizuka H, Azumi M, Kakizaki H, Tateno M, Celis E. Kobayashi H, et al. Cancer Res. 2007 Jun 1;67(11):5498-504. doi: 10.1158/0008-5472.CAN-07-0304. Cancer Res. 2007. PMID: 17545632 - Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
Piesche M, Hildebrandt Y, Zettl F, Chapuy B, Schmitz M, Wulf G, Trümper L, Schroers R. Piesche M, et al. Hum Immunol. 2007 Jul;68(7):572-6. doi: 10.1016/j.humimm.2007.03.007. Epub 2007 Apr 11. Hum Immunol. 2007. PMID: 17584578 - Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F, Oka Y, Tsuboi A, Kawakami M, Kawakatsu M, Nakajima H, Elisseeva OA, Harada Y, Ito K, Li Z, Tatsumi N, Sakaguchi N, Fujioka T, Masuda T, Yasukawa M, Udaka K, Kawase I, Oji Y, Sugiyama H. Fujiki F, et al. J Immunother. 2007 Apr;30(3):282-93. doi: 10.1097/01.cji.0000211337.91513.94. J Immunother. 2007. PMID: 17414319 - Identification of T-cell epitopes for cancer immunotherapy.
Kessler JH, Melief CJ. Kessler JH, et al. Leukemia. 2007 Sep;21(9):1859-74. doi: 10.1038/sj.leu.2404787. Epub 2007 Jul 5. Leukemia. 2007. PMID: 17611570 Review. - Identification of MHC class II-restricted tumor antigens recognized by CD4+ T cells.
Wang RF. Wang RF. Methods. 2003 Mar;29(3):227-35. doi: 10.1016/s1046-2023(02)00345-6. Methods. 2003. PMID: 12725788 Review.
Cited by
- Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.
Alarcon NO, Jaramillo M, Mansour HM, Sun B. Alarcon NO, et al. Pharmaceutics. 2022 Jul 11;14(7):1448. doi: 10.3390/pharmaceutics14071448. Pharmaceutics. 2022. PMID: 35890342 Free PMC article. Review. - Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.
Balhorn R, Balhorn MC. Balhorn R, et al. Oncotarget. 2020 Sep 1;11(35):3315-3349. doi: 10.18632/oncotarget.27709. eCollection 2020 Sep 1. Oncotarget. 2020. PMID: 32934776 Free PMC article. - MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition.
Gu X, Mao Y, Shi C, Ye W, Hou N, Xu L, Chen Y, Zhao W. Gu X, et al. Onco Targets Ther. 2019 Sep 24;12:7843-7855. doi: 10.2147/OTT.S213164. eCollection 2019. Onco Targets Ther. 2019. PMID: 31576142 Free PMC article. - The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design.
Besneux M, Greenshields-Watson A, Scurr MJ, MacLachlan BJ, Christian A, Davies MM, Hargest R, Phillips S, Godkin A, Gallimore A. Besneux M, et al. Cancer Immunol Immunother. 2019 Feb;68(2):247-256. doi: 10.1007/s00262-018-2266-1. Epub 2018 Nov 7. Cancer Immunol Immunother. 2019. PMID: 30406375 Free PMC article. - Post-transcriptional regulation of cancer/testis antigen MAGEC2 expression by TRIM28 in tumor cells.
Song X, Guo C, Zheng Y, Wang Y, Jin Z, Yin Y. Song X, et al. BMC Cancer. 2018 Oct 11;18(1):971. doi: 10.1186/s12885-018-4844-1. BMC Cancer. 2018. PMID: 30309319 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials